Clinical Trial Update: Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer [Phase 2]

View source ↗

Summary

This update describes a Phase 2 clinical trial evaluating Everolimus in patients with progressive, recurrent, unresectable, or metastatic thyroid cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thyroid Cancer

Drugs mentioned

• Everolimus (everolimus)

Snippet

Sponsor: Leiden University Medical Center | Conditions: Head and Neck Cancer | Phase 2 | Status: UNKNOWN